Approval · Notice of Compliance 31871 · 2023
MYFEMBREE: Notice of Compliance 31871
Issued October 17, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31871
- Date
- October 17, 2023
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYFEMBREE | Not yet assigned | — |
Medicinal ingredients
- ESTRADIOL 1 MG per TAB
- NORETHINDRONE ACETATE 0.5 MG per TAB
- RELUGOLIX 40 MG per TAB